Assessing the Potential Apoptotic Effects of Different Hydatid Cyst Fluids on Human Healthy Hepatocytes and Hepatocellular Carcinoma Cells

İpek Baysal,Serra Örsten,Görkem Cengiz,Emre Ünal,Ahmet Bülent Doğrul,Türkmen Çiftçi,Samiye Yabanoğlu Çiftçi,Devrim Akinci,Okan Akhan
DOI: https://doi.org/10.1007/s11686-024-00797-z
2024-02-20
Acta Parasitologica
Abstract:Cystic Echinococcosis (CE) is a zoonotic infection caused by the larval form of Echinococcus granulosus in humans. Emerging evidence suggests an intriguing inverse association between E. granulosus infection and the occurrence of cancer. This study aimed to investigate the influence of diverse host-derived hydatid cyst fluids (HCF) with distinct genotypes on human liver hepatocytes (HC) and hepatocellular carcinoma cells (HepG2). Specifically, we examined their effects on cell proliferation, apoptosis sensitivity (BAX/BCL-2), apoptosis-related p53 expression, and the expression of cancer-related microRNA (hsa-miR-181b-3p). Cell proliferation assays, real-time PCR, and ELISA studies were conducted to evaluate potential anti-cancer properties. The findings revealed that animal-origin HCF (G1(A)) induced direct cell death by augmenting the susceptibility of HepG2 cells to apoptosis. Treatment with both G1(A) and G1(H) HCF sensitized HepG2 and HC cell lines to apoptosis by modulating the BAX/BCL-2 ratio, accompanied by upregulation of the p53 gene. Additionally, G1(A) HCF and human-derived HCFs (G1(H), G7(H)) reduced the expression of miR-181b-3p in HepG2 cells. Consequently, this study demonstrates the potential anti-cancer effect of HCF in HepG2 cells and provides the first comparative assessment of HCFs from human and animal sources with diverse genotypes, offering novel insights into this field.
parasitology,zoology,veterinary sciences
What problem does this paper attempt to address?
The paper aims to explore the anticancer properties of hydatid cyst fluid (HCF) from different genotypic sources on healthy human liver cells (HC) and hepatocellular carcinoma cells (HepG2). Specifically, the study evaluates the effects of HCF from different hosts (humans and animals) on cell proliferation, apoptosis sensitivity (measured by BAX/BCL-2 protein levels), p53 gene expression, and the expression of cancer-related microRNA (hsa-miR-181b-3p). The main findings include: 1. Animal-derived G1(A) HCF induces direct cell death in HepG2 cells, increasing sensitivity to apoptosis. 2. G1(A) and G1(H) HCF treatments make HepG2 and HC cell lines more sensitive to apoptosis, accompanied by upregulation of the p53 gene. 3. G1(A) HCF and human-derived HCFs (G1(H), G7(H)) reduce the expression of miR-181b-3p in HepG2 cells. 4. These results suggest that HCF may have anticancer properties and provide the first comparative study of HCF from different genotypic sources. In summary, this study aims to explore the potential role and molecular mechanisms of HCF from different sources and genotypes in anticancer mechanisms.